-- Bank of America, Gannett, Gilead, Schwab: U.S. Equity Movers
-- Nikolaj Gammeltoft
-- 2010-07-16T20:34:46Z
-- http://www.bloomberg.com/news/2010-07-15/advanced-micro-goldman-sachs-google-people-s-lsb-u-s-equity-preview.html

          
          
             Shares of the following companies
had unusual moves in U.S. trading. Stock symbols are in
parentheses, and prices are as of 4 p.m. in New York.  
 Financial shares declined after  Bank of America Corp.  (BAC
US) and  Citigroup Inc.  (C US) reported a drop in second-quarter
earnings and said stock buybacks aren’t imminent.  
 Bank of America dropped the most in the Dow Jones
Industrial Average, sinking 9.2 percent to $13.98. Citigroup
fell 6.3 percent to $3.90.  Fifth Third Bancorp.  (FITB US)
slipped 8.2 percent to $12.17.  Marshall & Ilsley Corp.  (MI US)
lost 7.3 percent to $7.62.  SunTrust Banks Inc.  (STI US)
decreased 7.5 percent to $23.31.  Comerica Inc.  (CMA US) sank 6.8
percent to $36.17.  
 AVI BioPharma Inc.  (AVII US) rallied 11 percent, the most
since Dec. 2, to $1.81. The biotechnology company focusing on
cardiovascular and infectious diseases said it won a contract
from the U.S. government with potential funding of as much as
$291 million.  
 Charles Schwab Corp.  (SCHW US) rose the most in the
Standard & Poor’s 500 Index, climbing 4.1 percent to $15.14. The
largest independent brokerage by client assets reported second-
quarter profit that beat the average analyst estimate as revenue
from earned interest offset a drop in trading.  
 Gannett Co.  (GCI US) dropped 11 percent, the most since
June 3, to $13.50. The owner of USA Today and television
stations said second-quarter revenue fell to $1.37 billion,
missing the $1.39 billion average analyst forecast. Revenue at
Gannett has declined for the past three years.  
 Other newspaper publishers also retreated.  New York Times
Co.  (NYT US) fell 8.1 percent to $8.80.  McClatchy Co.  (MNI US)
declined 8.5 percent to $3.44.  
 General Electric Co.  (GE US) slipped 4.6 percent, the most
since May 20, to $14.55. The world’s biggest maker of jet
engines, power-generation equipment and locomotives reported
quarterly sales decreased 4.3 percent to $37.4 billion, trailing
the $38.3 billion average analyst estimate.  
 Gilead Sciences Inc.  (GILD US) slid 8.5 percent, the most
since April 21, to $31.94. Sanford C. Bernstein & Co. downgraded
the world’s largest maker of AIDS drugs to “market perform” from
“outperform” citing increased competition in the HIV market.  
 Google Inc.  (GOOG US) slid 7 percent, the most since April
16, to $459.61. The owner of the world’s most popular search
engine reported second-quarter profit that missed analysts’
estimates as the company ramped up spending.  
 Mattel Inc.  (MAT US) fell 9.5 percent, the most since Feb.
6, to $20.81. The world’s largest toymaker posted second-quarter
profit of 14 cents a share, missing the average analyst estimate
of 15 cents.  
 People’s United Financial Inc.  (PBCT US) fell 3.7 percent,
the most since May 27, to $13.63. The Bridgeport-Connecticut-
based lender agreed to buy  LSB Corp.  (LSBX US), the holding
company of RiverBank in Andover, Massachusetts, for $96 million
and  Smithtown Bancorp Inc.  (SMTB US), based in Hauppauge, New
York, for about $60 million. LSB rallied 46 percent to $20.60.  
      Polycom Inc.  (PLCM US) had the second-biggest decline in
the Russell 1000 Index, losing 10 percent to $28.75. The largest
independent maker of videoconferencing systems posted quarterly
earnings of 31 cents a share excluding some items, missing the
average analyst estimate by 3.1 percent, according to data
compiled by Bloomberg.  
 RealD Inc.  (RLD US) surged 22 percent to $19.51 on the
first day of trading. The maker of 3-D movie projectors used to
show James Cameron’s “Avatar” priced its initial public
offering above the forecast range yesterday, as demand for
technology IPOs picked up.  
 Vivus Inc.  (VVUS US) plunged 55 percent to $5.40 for the
biggest decline in Russell 2000 Index. The drugmaker was cut to
“neutral” at JPMorgan Chase & Co. and “underperform” at
Jefferies Group Inc. Yesterday, the Mountain View, California-
based company failed to win a U.S. panel’s backing to sell the
first new prescription diet pill in more than a decade.  
 Orexigen Therapeutics Inc.  (OREX US), which expects a
decision on its Contrave drug by Jan. 31, slid 9.4 percent to
$4.53.  
 JPMorgan raised competitor  Arena Pharmaceuticals Inc.  (ARNA
US) to “overweight” from “neutral,” saying its lorcaserin
“has the best shot at approval.” The shares rallied 19 percent
to $4.66 for the biggest gain in Russell 2000 Index.  
 To contact the reporter on this story:
 Nikolaj Gammeltoft  in New York at 
 ngammeltoft@bloomberg.net .  
          
          


  


        